somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Cave 83 (Treasure Cave C) is part of the compact group of the four "Treasure Caves" (82, 83, 84, 85) located at the entrance of the central valley. It is a relatively small square cave (3.6x3.6m), with a podium in the middle, probably for a statue or a stupa. Here the ceiling has collapsed, but probably formed a cupola. The back wall had a well-preserved scene of a Jataka story, the Rudrayana Legend from the Divyavadana, with king Rudrayana observing the dance of his Queen Chandraprabha, who appears nude except for thin veils and jewelry. During the dance, the king had a premonition that his wife would soon die, and she asked to become a Buddhist nun. The style and attitudes of the figures are generally Indian, such as the Tribhanga posture of the dancer, of the way the King is seated. The flutering ribbons of the diadem worn by the king however, were adopted from Iranian royal symbolism. In this cave, the frames of the paintings, especially the vine rinceaux, are probably derived from Roman art of the 1st century CE. This cave may be slightly earlier then Cave 84. The mural was sent to Berlin by Grünwedel (Ref: MIK III 8443). These paintings are soft and delicate: volumes are defined by gradations of shades and colors, not by the sharp limit of a line. Overall, "the brush has the priority over drawing".
== Career == As a high-school student, Wolpaw wrote two games for the Atari 8-bit computers published as type-in programs in Antic magazine in 1983 and 1984. From 1997 to 2002, Wolpaw and Chet Faliszek wrote the video game-oriented website Old Man Murray. The site was highly influential in video game writing and game journalism. He also wrote for GameSpot. He subsequently worked at Double Fine Productions as a writer for Psychonauts. In 2006, he won the Game Developers Choice Award for Best Writing for his story and dialogue contributions to Psychonauts. In 2004, Wolpaw joined Valve, where he and Faliszek wrote for games such as Half-Life 2: Episode One, Half-Life 2: Episode Two, Team Fortress 2, Left 4 Dead, Portal and Portal 2. He left Valve in February 2017 to write for Psychonauts 2, though he ended up not working on it. In January 2019, he confirmed that he had returned to Valve as a part-time contractor on Artifact and Half-Life: Alyx.
Ephedrine and pseudoephedrine are also relative, not absolute, contraindications. They are generally avoided or used only cautiously at reduced doses with monitoring because they may raise blood pressure. Pseudoephedrine is less potent than ephedrine, and ephedrine is less potent than amphetamine. Phenelzine generally does not need to be stopped before surgery solely because anesthesia is planned. Modern guidance states that MAOI treatment should not be discontinued without conferring with the prescribing psychiatrist, because depressive relapse risk may outweigh perioperative interaction risk when anesthetic and analgesic agents are chosen carefully. In perioperative care, the main drugs to avoid are those with significant serotonin reuptake inhibition or serotonin-releasing activity, especially serotonergic opioid analgesics such as meperidine (pethidine) and tramadol. Other opioids listed as serotonergic or uncertain-risk include methadone, tapentadol, dextromethorphan, dextropropoxyphene, pentazocine, and levorphanol. Other perioperative agents requiring avoidance or special caution include pancuronium, a muscle relaxant sometimes used with general anesthetics, and methylene blue, which has clinically relevant MAOI activity itself. These are not avoided because they are serotonin reuptake inhibitors. Direct-acting vasopressors such as epinephrine, norepinephrine, and phenylephrine are not absolute contraindications, but lower initial doses and careful titration are advised because their pressor effects may be potentiated.
Sources: en.wikipedia.org
CoWIN (Covid Vaccine Intelligence Network) is an Indian government web portal for COVID-19 vaccination registration, owned and operated by India's Ministry of Health and Family Welfare. It displays booking slots of COVID-19 vaccine available in the nearby areas and can be booked on the website. The site also provides vaccination certificates to the beneficiaries, which act as vaccine passports for the beneficiaries and can be stored in Digilocker. Users can access the platform via desktop, tablet, and mobile phones.
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.
Eclabium means the turning outwards of the lip. Eclabium comes from the Greek word "ek" meaning "out," and the Latin word "labium" meaning "lip." This deformation occurs in most babies born with harlequin type ichthyosis, caused by genetic defects. Eclabium can severely impact the quality of life. There are ways to predict if a child will have this condition before they are born through genetic testing. For patients who develop eclabium due to improper wound healing, there are different treatment options available to restore the lips back to normal or at least to the point where they are not a hazard to the patients quality of life. Periodontitis can also cause eclabium. As eclabium is a symptom, it is treated by addressing its cause. When the underlying disease is treated, the eclabium tends to go away as well.
Sources: en.wikipedia.org
==== Treatment and management ==== Adoption of healthy lifestyle practices and metformin medication are recommended as initial treatments. Lifestyle changes include daily exercise for at least 60 minutes, reduced screen time, and dietary education. Metformin at 500 mg per day is used upon diagnosis. Insulin is used for children with a blood glucose of more than 250 mg per dl and a HbA1C greater than 8.5%.
Enocyanin is a natural colorant extracted from the peels of black grapes (primarily Vitis vinifera). It is a mixture composed primarily of anthocyanins, particularly malvidin-3-glucoside (C23H25O12+). It is part of the water-soluble pigments belonging to the flavonoid class.
Transcription of insulin is regulated by the binding of various transcription factors to the ~400 base pairs before the insulin transcription start site, called the "insulin regulatory sequence". This sequence is made up of several distinct regions with different biochemical properties, each of which serve as binding sites for distinct regulatory proteins. First, multiple A/T-rich sequences, called "A elements", each of which contains a "TAAT" reocognized by homeodomain proteins. These regions are primarily bound by PDX-1, but also Cdx2 and Isl-1. Second, two so-called "C elements" – C1 located 107–118 base pairs before the transcription start site; C2 311–317 base pairs before the start site. C1 is bound by RIPE3b1 via MafA. C2 (also called the "pancreatic islet cell enhancer sequence" or "PISCES") is bound by PAX6. Third, an "E element" (two in rodents) with sequence GCCATCTG is 91–100 base pairs before the transcription start site and binds the helix-loop-helix transcription factors NEUROD1. Lastly, several "cyclic AMP response elements" with sequence TGACGTCA that binds CREB. In humans, a "Z-element" resides 243–292 base pairs before the start site and binds a complex called ZaI, as well as PDX-1 and MafA.
Deficiency of zinc intake affects about two billion people in the developing world and is associated with many diseases. In children, deficiency causes growth retardation, delayed sexual maturation, infection susceptibility, and diarrhea. However, consumption of excess zinc may cause ataxia, lethargy, and copper deficiency. In marine biomes, notably within polar regions, a deficit of zinc can compromise the vitality of primary algal communities, potentially destabilizing the intricate marine trophic structures and consequently impacting biodiversity. Brass, an alloy of copper and zinc in various proportions, was used as early as the third millennium BC in the Aegean area and the region which currently includes Iraq, the United Arab Emirates, Kalmykia, Turkmenistan and Georgia. In the second millennium BC it was used in the regions currently including West India, Uzbekistan, Iran, Syria, Iraq, and Israel. Zinc metal was not produced on a large scale until the 12th century in India, though it was known to the ancient Romans and Greeks. The mines of Rajasthan have given definite archeological evidence of zinc production harking back to the 6th century BC. The oldest man-made pure zinc comes from Zawar, Rajasthan, as early as the 9th century AD, when a distillation process was utilized to make virtually pure zinc. Alchemists would burn zinc metal in air to form what they called "philosopher's wool" or "white snow" (zinc oxide, ZnO). The element was probably named by the alchemist Paracelsus after the German word Zinke (prong, tooth).
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.